By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Signal Genetics today said that it will use its MyPRS genomic testing platform in a multiple myeloma research program being conducted by Array BioPharma.

According to the New York-based firm, it will provide Array BioPharma with genetic information from patient samples in two upcoming clinical studies on an Array drug candidate. It said that the collaboration may lead to the development of "superior and personalized treatment options for myeloma patients."

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.